抗人CD19单抗（克隆号FMC63）引用文献
抗人CD19单克隆抗体（克隆号FMC63）引用文献如下：
1. CD19 CAR antigen engagement mechanisms and affinity tuning
2. Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study
3. Solving the mystery of the FMC63-CD19 affinity
4.The costimulatory domain influences CD19 CAR-T cell resistance development in B-cell malignancies
5.Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy
6.Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus
7.Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients
8.Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics
9.Preclinical specificity & activity of a fully human 41BB-expressing anti-CD19 CART- therapy for treatment-resistant autoimmune disease
10.HLA-independent T cell receptors for targeting tumors with low antigen density
11.Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials
12.An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL
13.A preclinical study of allogeneic CD19 chimeric antigen receptor double‐negative T cells as an off‐the‐shelf immunotherapy drug against B‐cell malignancies
14.Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies
15.Hypoimmunogenic CD19 CAR-NK cells derived from embryonic stem cells suppress the progression of human B-cell malignancies in xenograft animals
16.Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers
17.CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic Reticulum
18.CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated
19.CAR T cells outperform CAR NK cells in CAR-mediated effector functions in head-to-head comparison
20.CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
……
Syd Labs抗人CD19重组抗体（克隆号FMC63）：
Syd Labs 重组抗人CD19单克隆抗体（克隆号FMC63），小鼠IgG2a Kappa，体内实验级（In vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody (Clone: FMC63), Mouse IgG2a Kappa, 货号：PA007271.m2a）是用哺乳动物细胞生产的重组抗体，可用于ELISA，流式细胞术（FC），中和（neutralization），功能测定如生物分析 PK 和 ADA 测定，以及那些用于研究受人 CD19蛋白影响的生物学途径的测定。
如果需要了解更多有关Syd Labs 重组抗人CD19单抗(克隆号FMC63)信息，比如Syd Labs 抗人CD19单抗使用说明等资料，欢迎联系多找找获取。
特此声明：多找找推广的所有产品和服务的价格、货期和规格等信息如有更改，恕不另行通知。除非另有说明，多找找推广的所有目录和定制产品仅限于科研使用，不得用于人类或动物的诊断或治疗。